



89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegzofermin at EASL International Liver Congress 2023

June 7, 2023

SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that pegozafermin data in nonalcoholic steatohepatitis (NASH) will be featured in a late-breaker oral presentation during the European Association for the Study of the Liver (EASL) Congress 2023 to be held June 21-24, 2023 in Vienna, Austria. The presentation was selected for inclusion in the Best of EASL Congress summary slide deck that highlights the most noteworthy contributions to the scientific program at EASL.

Details for the late-breaker oral presentation are as follows:

Abstract Title: Pegzofermin for the treatment of non-alcoholic steatohepatitis patients with F2/F3 fibrosis: a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial (ENLIVEN)

Abstract Number: LBO-05

Format: Oral presentation

Presenting Author: Rohit Loomba, M.D., MHSc, Director, NAFLD Research Center, University of California San Diego, and lead investigator of ENLIVEN

Presentation Date and Time: Saturday, June 24th 12:00-12:15 CET

89bio will also present data from a preclinical study. Presentation details are as follows:

Abstract Title: Pegzofermin inhibits NASH-induced hepatocellular carcinoma in the STAM™ mouse model

Abstract Number: SAT-243

Format: Poster

Presenting Author: Maya Margalit, M.D., of 89bio

Presentation Date and Time: Saturday, June 24th 9:00-17:00 CET

About 89bio

89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead therapeutic candidate, pegozafermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on [LinkedIn](#).

Investor Contact:

Ryan Martins
Chief Financial Officer
investors@89bio.com

PJ Kelleher

LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com

Media Contact:

Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com